gvtcx

NP47923b Tocilizumab

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£92,000,000
Statuscomplete
Category (CPV) 33600000
RegionScotland
Deadline21 Nov 2023
Procedureopen
OCIDocds-h6vhtk-040dc3

Awards (9)

This procurement was awarded to 9 suppliers. Values shown are per-award; the notice total is £92,000,000.

SupplierValueDateStatus
AbbVie Ltd shared · · active
Alexion Rare Disease part of Astra Zeneca shared · · active
Amgen Ltd shared · · active
Biogen Idec Ltd shared · · active
Celltrion Healthcare United Kingdom Limited shared · · active
Fresenius Kabi Limited shared · · active
Roche Products Ltd shared · · active
Samsung Bioepis shared · · active
Sandoz shared · · active

description

Supply of tocilizumab to NHS Scotland.

notice history

4 notices published against this procurement.

PublishedTypeRegimeNotice
20 Oct 2023 Contract notice (F02) Earlier regulations 031051-2023
7 Feb 2024 Contract award notice (F03) Earlier regulations 003972-2024
7 Feb 2024 Contract award notice (F03) Earlier regulations 003971-2024
7 Feb 2024 Contract award notice (F03) Earlier regulations 003970-2024

more from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.